TY - JOUR T1 - The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer JF - Anticancer Research JO - Anticancer Res SP - 5635 LP - 5641 DO - 10.21873/anticanres.16072 VL - 42 IS - 11 AU - TORU AOYAMA AU - YUKIO MAEZAWA AU - KENTARO HARA AU - MIWHA JU AU - KEISUKE KOMORI AU - HIROSHI TAMAGAWA AU - AYAKO TAMAGAWA AU - KEISUKE KAZAMA AU - SHO SAWAZAKI AU - ITARU HASHIMOTO AU - KAZUKI KANO AU - HARUHIKO CHO AU - JUNYA MORITA AU - KENKI SEGAMI AU - TETSUSHI ISHIGURO AU - TSUTOMU SATO AU - TAKASHI OSHIMA AU - NORIO YUKAWA AU - YASUSHI RINO Y1 - 2022/11/01 UR - http://ar.iiarjournals.org/content/42/11/5635.abstract N2 - Background/Aim: The present study evaluated the clinical impact of other metachronous or synchronous primary cancer (OPC) in patients who received curative treatment for esophageal cancer. Patients and Methods: The present study included 168 patients who underwent curative treatment for esophageal cancer between 2005 and 2018. Prognosis and differences between the OPC status (metachronous/synchronous) and clinic pathological parameters was analyzed. Results: A total of 168 patients were included in this study. Forty patients were diagnosed with metachronous/synchronous OPC. When comparing the clinicopathological factors between the patients with and without OPC, the patients’ background and postoperative clinical courses were very similar between the two groups. The 3- and 5-year overall survival rates in patients with esophageal cancer with OPC were 66.0% and 54.5%, respectively, while those in patients without OPC were 50.1% and 41.4%, respectively. There was no statistically significant difference in these rates (p=0.156). The OPC status was not included in the final multivariate analysis model. Conclusion: The OPC status was not found to be a prognostic factor for patients who received curative treatment for esophageal cancer. Therefore, it is not necessary to avoid performing curative treatment for esophageal cancer because of a patient’s OPC status. ER -